A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy
Brian C. Gilger(North Carolina State University), Matthew L. Hirsch(University of North Carolina at Chapel Hill)
Cited by 9
Related Papers
AAV Gene Therapy for MPS1-associated Corneal Blindness
|Scientific Reports|2016|50
AAV vector transduction restriction and attenuated toxicity in hESCs via a rationally designed inverted terminal repeat
|Nucleic Acids Research|2025|7